DOCSLIB.ORG

Conference 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Conference 2016 Conference 2016: From Drug Discovery to Health Outcomes: Population to Patient May 31 - June 3, 2016 River Rock Resort, Richmond, BC Canada A joint conference of: Canadian Society for Pharmaceutical Sciences Canadian Chapter of Controlled Release Society Conference Chair: Frank Abbott, University of British Columbia, Vancouver, BC Conference Organizing Committee: Michael Coughtrie (UBC), Jason Crawford (Centre for Drug Research & Development), David Kwok (BRI Biopharmaceutical Research Inc.), Shyh-Dar Li (UBC), Larry Lynd (UBC), Corey Nislow (UBC), Simon Pimstone (Xenon Pharmaceuticals Inc.), Robert Young (Simon Fraser University) Staff: Bev Berekoff Barbara Scollick From Drug Discovery to Health Outcomes: Population to Patient | 1s Conference Program TUESDAY, MAY 31, 2016 8:00 AM Registration 9:00 - 5:00 Industry Day: Innovation and Management of Modern Pharmaceuticals (Whistler Ballroom B) 9:00 - 10:00 PLENARY 1: Carolyn Buser-Doepner, GSK New Trends in Pharma-Academia Collaborations for Drug Discovery Chair: Amyn Sayani, GSK SPONSORED BY: COLORCON 10:00-10:15 Refreshment and networking break Showcasing Drug Discovery Companies 10:15 - Chair: Jason Crawford, CDRD 11:00 Robin Sherrington, Xenon Pharmaceuticals Human Channelopathies: Providing Key Insights Into Drug Development Ernie McEachern, Alectos Therapeutics Alectos Therapeutics: Targeted Innovation in Preclinical Drug Discovery Novel Delivery Technologies for Therapeutics 11:00 - Chair: Pieter Cullis, UBC 12:30 John Babcook, Zymeworks Inc. Zymelink™ - Next Generation Drug Conjugates James Taylor, Precision Nanosystems The NanoAssemblr Platform: Microfluidic-based Manufacture of Nanomedicines from uLs to 10s L Michael Hope, Acuitas Therapeutics A Lipid Nanoparticle Platform to Enable mRNA Therapeutics 12:30 - 1:30 Lunch break and networking 1:30 - 2:30 Pharma at the Forefront in Drug Discovery Chair: Robert Young, SFU Jennifer Yearley, Merck Research Labs Translational Biology in the IO Space - Patient Response, Combination Therapies, New Approaches Anne Fourie, Janssen Pharmaceutical Research & Development Psoriasis - From Transformational Treatments to Cure and Interception 2:30 - 3:00 Refreshment and networking break New Commercialization Strategies, Regulatory Challenges, Big Data Issues 3:00 - 4:30 Chair: Jason Crawford, CDRD David Main, Aquinox, & Chair BIOTECanada New Commercialization Strategies Farzad Ali, Pfizer Access to New Medicines, Do Canadians Deserve Better? Paul Terry, PHEMI Health Systems Privacy, Governance & Innovation in the Era of Big Data 4:30 - 5:30 Closing Plenary: Chris Halyk, President, Janssen Inc. Are Innovative Medicines and our Life Sciences Industry at Risk in Canada? Chair: Catherine Lau, Janssen Inc. 5:30 - 7:00 Welcome Reception: CSPS, CC-CRS, AFPC SPONSORED BY JANSSEN INC. 2s | CSPS/CC-CRS Conference 2016, Vancouver, BC, Canada WEDNESDAY, JUNE 1 - MORNING SESSIONS 7:00 AM Registration and Poster Set-Up 7:30 - Trainee Mentoring Breakfast 9:00 9:00 - PLENARY LECTURE: Aaron Schimmer, Princess Margaret Cancer Centre 10:00 New Therapeutic Strategies to Target the Mitochondria in Leukemia Chair: Corey Nislow, UBC 10:00 - Refreshment Break: Posters, Exhibitors, and Networking (Theatre) 10:30 10:30 - SESSION 1: Special Populations SPONSORED BY: SANDOZ CANADA 12:00 Chair: Abby Collier, UBC SESSION 2: Regulatory Challenges and Opportunities Chair: Fakhreddin Jamali, University of Alberta (Whistler Ballroom A) (Whistler Ballroom B) 10:30 Pediatric Development of Metabolizing Enzymes Regulatory Issues on the Determination of Abby Collier, University of British Columbia Bioequivalence for Modified-Release Drug Products with Multiphasic Concentration Profiles Laszlo Endrenyi, Faculty of Medicine, University of Toronto 11:00 PBPK Modelling and Simulation in Pediatric Drug Current Status of Decision-making for Biosimilars in Development Canada Andrea Edginton, University of Waterloo Agnes Klein, Biologics and Genetics Therapy Directorate, Health Canada 11:30 Developmental Pharmacology – ADME Consequences in Challenges in Ensuring Drug Product Quality in the Children Product Lifecycle Catherijne Knibbe, Universiteit Leiden Krishnan Tirunellai, Therapeutic Products Directorate, Health Canada 12:00 - GSK/CSPS Early Career Award Lecture 12:30 Mary De Vera, UBC Patient Engagement in Medication Adherence Research Chair: Larry Lynd, UBC 12:30 - Lunch break 2:00 Posters, Exhibitors, and Networking (Theatre) From Drug Discovery to Health Outcomes: Population to Patient | 3s WEDNESDAY, JUNE 1 - AFTERNOON SESSIONS 2:30 - SESSION 3: Nanomedicines Become Personal: SESSION 4: Broaching the Fourth Hurdle: Getting 5:10 Opportunities and Challenges Drugs on the Formulary Co-Chairs: Shyh-Dar Li, UBC, and Amy Lee, Arbutus Chair: Larry Lynd, UBC Biopharma (Whistler Ballroom B) (Whistler Ballroom A) 2:30 Image-guided Focused Ultrasound for Targeted Delivery (2:30) Orphan Drugs-Catastrophic Drug Coverage of Drugs Fred Horne, Horne and Associates Kullervo Hynynen, Sunnybrook Res. Institute 3:00 Personalize Nanomedicines by Developing (2:45) Developing Specialty Drugs for a Conditional Multifunctional Nanoparticles and Identifying Reimbursement Environment: Is Quicker Necessarily Therapeutic Biomarkers Better? Shyh-Dar Li, UBC Chris McCabe, University of Alberta 3:30 Refreshment Break: Posters, Exhibitors, and Networking (Theatre) 4:00 Porphysome Nanotechnology: Discovery and Road to (3:00) Perspectives from a Public Drug Plan on the Clinical Translation Challenges and Opportunities with Expensive Drugs for Gang Zheng, Ontario Cancer Institute Rare Diseases (EDRD) Eric Lun, B.C. Ministry of Health (3:15) The Complexity in Making Reimbursement 4:30 TKM-Ebola and TKM-Ebola-Guinea: Rapid Re- Decisions around Expensive Drugs for Rare Diseases development of a Nucleic Acid Therapeutic in Response Doug Coyle, University of Ottawa to the West Africa Outbreak Amy Lee, Arbutus Biopharma Corporation (4:00 - 5:00) Panel Discussion 5:00 - Oral Presentation from Posters: Oral Presentation from Posters: 5:15 Polymer-Lipid Based Nanomedicine of Synergistic Drug Preferences for Donating Money to Support Drug Combination for Improving Chemotherapy of Multidrug Development Research Projects in a Sample of Resistant Breast Cancer Canadian and U.S. Adults Rui Xue Zhang, University of Toronto Nick Dragojlovic, University of British Columbia 5:15 - Posters, Exhibitors, and Networking (Theatre) 6:00 4s | CSPS/CC-CRS Conference 2016, Vancouver, BC, Canada THURSDAY, JUNE 2 - MORNING SESSIONS 7:00 AM Registration and Poster Set-up 7:30 - Breakfast Lectures: Medical Marijuana 9:00 Chair: Frank Abbott, UBC Jonathan Page, UBC Chemical and Genomic Analysis of Cannabis Caroline MacCallum, Greenleaf Medical Clinic, & UBC Hospital Medical Clinic, Vancouver Medical Cannabis and Cannabinoids 9:00 - PLENARY LECTURE: Ivana Cecic , Genome BC 10:00 Genomics in Canada: From Knowledge Generation to Patient Outcomes Chair: Corey Nislow, UBC 10:00-- Refreshment Break: Posters, Exhibitors, and Networking (Theatre) 10:30 BREAK SPONSORED BY MSFHR 10:30 - SPONSORED BY: GENOME BC SESSION 6: Responsive Drug Delivery Systems 12:00 SESSION 5: Pharmacogenomics in the Clinic and Community Co-Chairs: Todd Hoare, McMaster University and Marc Gauthier, INRS Chair: Corey Nislow, UBC (Whistler Ballroom A) (Whistler Ballroom B) (10:30-10:40) Trainee Presentation: Complete 10:30 Harnessing the Power of Synthetic Lethality: Regression of Xenograft Tumors upon Targeted Delivery Identifying and Targeting Dependencies in Cancer of Paclitaxel via Π-Π Stacking Stabilized Polymeric Lisa Belmont, Genentech Micelles Roy van der Meel, Utrecht University / UBC Smart Automated Release, Because Drugs Don't Work in Patients who Don't Take Them Adah Almutairi, University of California, San Diego 11:00 Implementation of Pharmacogenomics for the Poly(2-oxazoline) Biomaterials Prevention of Severe Adverse Drug Reactions in Richard Hoogenboom, Ghent University, Belgium Pediatric Oncology Colin Ross, UBC and CFRI 11:30 UBC - GenomeBC - BCPhA Project "Bio-hybrid" Therapeutics Corey Nislow, UBC Marc Gauthier, Institut National de la Recherche Scientifique (INRS) 12:00 - CSPS Lifetime Achievement Award Lecture 12:30 Fakhreddin Jamali, University of Alberta Pharmaceutical Research and Development, Lessons Learned Chair: Raimar Loebenberg (Whistler Ballroom A) 12:30 - 12:30 - Annual Meetings: CSPS (Ballroom A) & CC-CRS (Ballroom B) 2:30 Lunch Break Posters, Exhibitors, and Networking (Theatre) From Drug Discovery to Health Outcomes: Population to Patient | 5s THURSDAY, JUNE 2 - AFTERNOON SESSIONS 2:30 - SPONSORED BY: ZYMEWORKS SESSION 8: Health Sustainability SESSION 9: JOINT Session with 5:00 Evidence AFPC SESSION 7: Drug Targeting and Targeting Drugs Chair: Mark Harrison, UBC Chair: Simon Albon, UBC Chair: Robert Young, SFU (Whistler Ballroom A) (Whistler Ballroom B) (Fraser Room) 2:30 Targeted and Stimuli-sensitive Role of Patient Reported Outcome Integrating Pharmaceutical Combination siRNA/Drug Measures (PROMs) in the Ongoing Sciences into a Pharm D Curriculum Nanopreparations for Multidrug Evaluation of Treatment and Scott Singleton, The University of Resistant Cancer Reimbursement North Carolina at Chapel Hill Vladimir Torchilin, Northeastern Stirling Bryan, UBC/Centre for University Clinical Epidemiology & Evaluation (C2E2) Roundtable Discussion 3:00 Advancements in Antibody Drug Patient Reported Outcome Conjugate Technology Measures (PROMs) and Patient Django Sussman, Seattle Genetics, Decision Making Inc. Mark Harrison, UBC 3:30 Refreshment
Load more

Recommended publications
  • Effect of Bioactive Compound of Aronia Melanocarpa on Cardiovascular System in Experimental Hypertension
    Hindawi Oxidative Medicine and Cellular Longevity Volume 2017, Article ID 8156594, 8 pages https://doi.org/10.1155/2017/8156594 Research Article Effect of Bioactive Compound of Aronia melanocarpa on Cardiovascular System in Experimental Hypertension 1 1 1,2 1 Martina Cebova, Jana Klimentova, Pavol Janega, and Olga Pechanova 1Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, Slovakia 2Department of Pathology, Faculty of Medicine, Comenius University, Bratislava, Slovakia Correspondence should be addressed to Martina Cebova; [email protected] Received 4 August 2017; Revised 10 October 2017; Accepted 18 October 2017; Published 30 November 2017 Academic Editor: Victor M. Victor Copyright © 2017 Martina Cebova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Aronia melanocarpa has attracted scientific interest due to its dense contents of different polyphenols. We aimed to analyse effects of Aronia melanocarpa (AME) extract on blood pressure (BP), lipid peroxidation, cytokine level, total NOS activity in the left ventricle (LV), and aorta of L-NAME-induced hypertensive rats. 12-week-old male WKY rats were assigned to the control group and groups treated with AME extract (57.90 mg/kg/day), L-NAME (40 mg/kg/day), or combination of L-NAME (40 mg/kg/day) and AME (57.90 mg/kg/day) in tap water for 3 weeks. NOS activity, eNOS protein expression, and conjugated diene (CD) concentration were determined in the LV and aorta. After 3 weeks of L-NAME treatment, BP was increased by 28% and concomitant treatment with AME reduced it by 21%.
    [Show full text]
  • Relationships Between the Content of Phenolic Compounds and the Antioxidant Activity of Polish Honey Varieties As a Tool for Botanical Discrimination
    molecules Article Relationships between the Content of Phenolic Compounds and the Antioxidant Activity of Polish Honey Varieties as a Tool for Botanical Discrimination Monika K˛edzierska-Matysek 1, Małgorzata Stryjecka 2, Anna Teter 1 , Piotr Skałecki 1, Piotr Domaradzki 1 and Mariusz Florek 1,* 1 Institute of Quality Assessment and Processing of Animal Products, University of Life Sciences in Lublin, Akademicka 13, 20-950 Lublin, Poland; [email protected] (M.K.-M.); [email protected] (A.T.); [email protected] (P.S.); [email protected] (P.D.) 2 Institute of Agricultural Sciences, State School of Higher Education in Chełm, Pocztowa 54, 22-100 Chełm, Poland; [email protected] * Correspondence: mariusz.fl[email protected]; Tel.: +48-81-4456621 Abstract: The study compared the content of eight phenolic acids and four flavonoids and the antioxidant activity of six Polish varietal honeys. An attempt was also made to determine the correlations between the antioxidant parameters of the honeys and their polyphenol profile using principal component analysis. Total phenolic content (TPC), total flavonoid content (TFC), antioxidant activity (ABTS) and reduction capacity (FRAP) were determined spectrophotometrically, and the phenolic compounds were determined using high-performance liquid chromatography (HPLC). The buckwheat honeys showed the strongest antioxidant activity, most likely because they had the highest Citation: K˛edzierska-Matysek,M.; concentrations of total phenols, total flavonoids, p-hydroxybenzoic acid, caffeic acid, p-coumaric acid, Stryjecka, M.; Teter, A.; Skałecki, P.; vanillic acid and chrysin. The principal component analysis (PCA) of the data showed significant Domaradzki, P.; Florek, M.
    [Show full text]
  • WO 2018/218208 Al 29 November 2018 (29.11.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/218208 Al 29 November 2018 (29.11.2018) W !P O PCT (51) International Patent Classification: Fabio; c/o Bruin Biosciences, Inc., 10225 Barnes Canyon A61K 31/00 (2006.01) A61K 47/00 (2006.01) Road, Suite A104, San Diego, California 92121-2734 (US). BEATON, Graham; c/o Bruin Biosciences, Inc., 10225 (21) International Application Number: Barnes Canyon Road, Suite A104, San Diego, California PCT/US20 18/034744 92121-2734 (US). RAVULA, Satheesh; c/o Bruin Bio (22) International Filing Date: sciences, Inc., 10225 Barnes Canyon Road, Suite A l 04, San 25 May 2018 (25.05.2018) Diego, Kansas 92121-2734 (US). (25) Filing Language: English (74) Agent: MALLON, Joseph J.; 2040 Main Street, Four teenth Floor, Irvine, California 92614 (US). (26) Publication Langi English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/5 11,895 26 May 2017 (26.05.2017) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/5 11,898 26 May 2017 (26.05.2017) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (71) Applicants: BRUIN BIOSCIENCES, INC. [US/US]; DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 10225 Barnes Canyon Road, Suite A104, San Diego, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, California 92121-2734 (US).
    [Show full text]
  • Influence of the Growing Conditions on the Flavonoids and Phenolic Acids
    Influence of the growing conditions on the flavonoids and phenolic acids accumulation in amaranth (Amaranthus hypochondriacus L.) leaves Influencia de las condiciones de crecimiento en la acumulación de flavonoids y ácidos fenólicos en hojas de amaranto (Amaranthus hypochondriacus L.) Ana P. Barba de la Rosa1 , Antonio de León-Rodríguez1 , Bente Laursen2, and Inge S. Fomsgaard2,‡ 1 Instituto Potosino de Investigación Científica y Tecnológica (IPICYT). Camino a la Presa San José 2055, Col. Lomas 4 sección. 78216, San Luis Potosí, San Luis Potosí, México. 2 Aarhus University, Faculty of Science and Technology, Department of Agroecology. AU Flakkebjerg Forsøgsvej 1 4200 Slagelse, Denmark. ‡ Corresponding author ([email protected]) SUMMARY RESUMEN Phytochemicals or phenolic compounds are Los f itoquímicos o compuestos fenólicos son important natural bioactive molecules that plants importantes moléculas bioactivas naturales que las accumulate in response to environmental conditions plantas acumulan en respuesta a las condiciones and may exert benef icial effects on health by protecting ambientales y que pueden ejercen efectos benéf icos humans against many diseases. The aim of this work para la salud protegiendo a los humanos de muchas was to analyze the influence of biotic and abiotic enfermedades. El objetivo de este trabajo fue analizar stress on the accumulation of flavonoids and phenolic la influencia del estrés biótico y abiótico en la acids on leaves of two cultivars of Amaranthus acumulación de flavonoides y ácidos fenólicos en las hypochondriacus, which are differentiated by the colour hojas de dos cultivares de Amaranthus hypochondriacus of their leaves (red or green). Phenolic compounds diferenciadas por el color de sus hojas (rojas y verdes).
    [Show full text]
  • Agastache Rugosa Alleviates the Multi-Hit Effect on Hepatic Lipid Metabolism, Infammation and Oxidative Stress During Nonalcoholic Fatty Liver Disease
    Agastache rugosa alleviates the multi-hit effect on hepatic lipid metabolism, inammation and oxidative stress during nonalcoholic fatty liver disease Yizhe Cui Heilongjiang Bayi Agricultural University https://orcid.org/0000-0002-7877-8328 Renxu Chang Heilongjiang Bayi Agricultural University Qiuju Wang Heilongjiang Bayi Agricultural University Yusheng Liang University of Illinois at Urbana-Champaign Juan J Loor University of Illinois at Urbana-Champaign Chuang Xu ( [email protected] ) Heilongjiang Bayi Agricultural University Research Keywords: NAFLD, Agastache rugosa, mice, AML12 cells, multi-targets Posted Date: April 21st, 2020 DOI: https://doi.org/10.21203/rs.3.rs-21957/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/24 Abstract Background Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, and has high rates of morbidity and mortality worldwide. Agastache rugosa (AR) possesses unique anti-oxidant, anti‐inammatory and anti-atherosclerosis characteristics. Methods To investigate the effects and the underlying mechanism of AR on NAFLD, we fed mice a high-fat diet (HFD) to establish NAFLD model of mice in vivo experiment and induced lipidosis in AML12 hepatocytes through a challenge with free fatty acids (FFA) in vitro. The contents of total cholesterol (TC), triglyceride (TG), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in liver homogenates were measured. Pathological changes in liver tissue were evaluated by HE staining. Oil red O staining was used to determine degree of lipid accumulation in liver tissue, and Western blot was used to detect abundance of inammation-, lipid metabolism- and endoplasmic reticulum stress-related proteins.
    [Show full text]
  • Journal of the Taiwan Institute of Chemical Engineers 42 (2011) 608–615
    Journal of the Taiwan Institute of Chemical Engineers 42 (2011) 608–615 Contents lists available at ScienceDirect Journal of the Taiwan Institute of Chemical Engineers journal homepage: www.elsevier.com/locate/jtice Correlation of solid solubilities for phenolic compounds and steroids in supercritical carbon dioxide using the solution model Chie-Shaan Su, Yen-Ming Chen, Yan-Ping Chen * Department of Chemical Engineering, National Taiwan University, Taipei, Taiwan ARTICLE INFO ABSTRACT Article history: The solid solubilities of phenolic compounds and steroids in supercritical carbon dioxide were correlated in Received 19 June 2010 this study using the solution model in its dimensionless form. The molar volume of solid solutes in Received in revised form 16 November 2010 supercritical carbon dioxide (V2) was taken as an adjustable parameter in this solution model. Their values Accepted 26 November 2010 for various solid solutes were determined from experimental solubility data at various temperatures and Available online 26 January 2011 pressures. The V2 parameters were well correlated with the densities of supercritical carbon dioxide. This correlation was further generalized to predict the solubility of complex solid in supercritical carbon Keywords: dioxide. The applicability of the solution model was presented in this study for two categories of phenolic Solubility and steroid compounds. The solution model with less parameters yielded comparably satisfactory results Supercritical carbon dioxide Solution model to those from commonly used semi-empirical models. The solution model with generalized parameters Phenolic compounds also yielded acceptable predicted results for these complex compounds. Steroids ß 2010 Taiwan Institute of Chemical Engineers. Published by Elsevier B.V. All rights reserved.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Heart Attack/Coronary Infarct
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Heart Attack/Coronary Infarct Chemical Activity Count (+)-ADLUMINE 1 (+)-ALPHA-VINIFERIN 1 (+)-AROMOLINE 1 (+)-BORNYL-ISOVALERATE 1 (+)-CATECHIN 5 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-GALLOCATECHIN 1 (+)-HERNANDEZINE 2 (+)-ISOCORYDINE 2 (+)-PRAERUPTORUM-A 1 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-ACETOXYCOLLININ 1 (-)-ALPHA-BISABOLOL 1 (-)-APOGLAZIOVINE 1 (-)-ARGEMONINE 1 (-)-BETONICINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 2 (-)-BORNYL-FERULATE 2 (-)-BORNYL-P-COUMARATE 2 (-)-CANADINE 1 (-)-DICENTRINE 1 (-)-EPICATECHIN 6 (-)-EPICATECHIN-3-O-GALLATE 1 Chemical Activity Count (-)-EPIGALLOCATECHIN 1 (-)-EPIGALLOCATECHIN-3-O-GALLATE 2 (-)-EPIGALLOCATECHIN-GALLATE 3 (-)-HYDROXYJASMONIC-ACID 1 (-)-N-(1'-DEOXY-1'-D-FRUCTOPYRANOSYL)-S-ALLYL-L-CYSTEINE-SULFOXIDE 1 (-)-SPARTEINE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 2 (2R)-(12Z,15Z)-2-HYDROXY-4-OXOHENEICOSA-12,15-DIEN-1-YL-ACETATE 1 (7R,10R)-CAROTA-1,4-DIENALDEHYDE 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 2 0-METHYLCORYPALLINE 2 1,2,6-TRI-O-GALLOYL-BETA-D-GLUCOSE 1 1,7-BIS(3,4-DIHYDROXYPHENYL)HEPTA-4E,6E-DIEN-3-ONE 1 1,7-BIS(4-HYDROXY-3-METHOXYPHENYL)-1,6-HEPTADIEN-3,5-DIONE 1 1,7-BIS-(4-HYDROXYPHENYL)-1,4,6-HEPTATRIEN-3-ONE 1 1,8-CINEOLE 3 1-(METHYLSULFINYL)-PROPYL-METHYL-DISULFIDE 1 1-ETHYL-BETA-CARBOLINE 1 1-O-(2,3,4-TRIHYDROXY-3-METHYL)-BUTYL-6-O-FERULOYL-BETA-D-GLUCOPYRANOSIDE 1 10-ACETOXY-8-HYDROXY-9-ISOBUTYLOXY-6-METHOXYTHYMOL
    [Show full text]
  • Aristolochia Species and Aristolochic Acids
    B. ARISTOLOCHIA SPECIES AND ARISTOLOCHIC ACIDS 1. Exposure Data 1.1 Origin, type and botanical data Aristolochia species refers to several members of the genus (family Aristolochiaceae) (WHO, 1997) that are often found in traditional Chinese medicines, e.g., Aristolochia debilis, A. contorta, A. manshuriensis and A. fangchi, whose medicinal parts have distinct Chinese names. Details on these traditional drugs can be found in the Pharmacopoeia of the People’s Republic of China (Commission of the Ministry of Public Health, 2000), except where noted. This Pharmacopoeia includes the following Aristolochia species: Aristolochia species Part used Pin Yin Name Aristolochia fangchi Root Guang Fang Ji Aristolochia manshuriensis Stem Guan Mu Tong Aristolochia contorta Fruit Ma Dou Ling Aristolochia debilis Fruit Ma Dou Ling Aristolochia contorta Herb Tian Xian Teng Aristolochia debilis Herb Tian Xian Teng Aristolochia debilis Root Qing Mu Xiang In traditional Chinese medicine, Aristolochia species are also considered to be inter- changeable with other commonly used herbal ingredients and substitution of one plant species for another is established practice. Herbal ingredients are traded using their common Chinese Pin Yin name and this can lead to confusion. For example, the name ‘Fang Ji’ can be used to describe the roots of Aristolochia fangchi, Stephania tetrandra or Cocculus species (EMEA, 2000). Plant species supplied as ‘Fang Ji’ Pin Yin name Botanical name Part used Guang Fang Ji Aristolochia fangchi Root Han Fang Ji Stephania tetrandra Root Mu Fang Ji Cocculus trilobus Root Mu Fang Ji Cocculus orbiculatus Root –69– 70 IARC MONOGRAPHS VOLUME 82 Similarly, the name ‘Mu Tong’ is used to describe Aristolochia manshuriensis, and certain Clematis or Akebia species.
    [Show full text]
  • Recent Advances in the Analysis of Phenolic Compounds in Unifloral
    molecules Review Recent Advances in the Analysis of Phenolic Compounds in Unifloral Honeys Marco Ciulu, Nadia Spano, Maria I. Pilo and Gavino Sanna * Dipartimento di Chimica e Farmacia, Università degli Studi di Sassari, via Vienna 2, 07100 Sassari, Italy; [email protected] (M.C.); [email protected] (N.S.); [email protected] (M.I.P.) * Correspondence: [email protected]; Tel.: +39-079-229500; Fax: +39-079-228625 Academic Editors: Maurizio Battino, Etsuo Niki and José L. Quiles Received: 28 January 2016; Accepted: 25 March 2016; Published: 8 April 2016 Abstract: Honey is one of the most renowned natural foods. Its composition is extremely variable, depending on its botanical and geographical origins, and the abundant presence of functional compounds has contributed to the increased worldwide interest is this foodstuff. In particular, great attention has been paid by the scientific community towards classes of compounds like phenolic compounds, due to their capability to act as markers of unifloral honey origin. In this contribution the most recent progress in the assessment of new analytical procedures aimed at the definition of the qualitative and quantitative profile of phenolic compounds of honey have been highlighted. A special emphasis has been placed on the innovative aspects concerning the extraction procedures, along with the most recent strategies proposed for the analysis of phenolic compounds. Moreover, the centrality of validation procedures has been claimed and extensively discussed in order to ensure the fitness-for-purpose of the proposed analytical methods. In addition, the exploitation of the phenolic profile as a tool for the classification of the botanical and geographical origin has been described, pointing out the usefulness of chemometrics in the interpretation of data sets originating from the analysis of polyphenols.
    [Show full text]
  • Correlation for the Solubilities of Pharmaceutical Compounds in Supercritical Carbon Dioxide
    Fluid Phase Equilibria 254 (2007) 167–173 Correlation for the solubilities of pharmaceutical compounds in supercritical carbon dioxide Chie-Shaan Su, Yan-Ping Chen ∗ Department of Chemical Engineering, National Taiwan University, Taipei, Taiwan, ROC Received 23 December 2006; received in revised form 28 February 2007; accepted 1 March 2007 Available online 6 March 2007 Abstract The solid solubilities of pharmaceutical compounds in supercritical carbon dioxide were correlated using the regular solution model with the Flory–Huggins equation. The pharmaceutical compounds include steroids, antioxidants, antibiotics, analgesics and specific functional drugs. The molar volumes of these solid solutes in supercritical carbon dioxide were taken as the empirical parameters in this study. They were optimally fitted for each pharmaceutical compound using the experimental solid solubility data from literature. The logarithms of the molar volumes of these solutes were then correlated as a linear function of the logarithms of the densities for supercritical carbon dioxide. With one or two parameters in this linear equation, satisfactory solid solubilities were calculated that were comparable to those from the commonly used semi-empirical equations with more adjustable parameters. The parameters of this model were further generalized as a function of the properties of the pharmaceutical compounds. It was observed that the prediction of solubilities of pharmaceutical compounds in supercritical carbon dioxide was within acceptable accuracy for more than 50% of the systems investigated in this study. © 2007 Elsevier B.V. All rights reserved. Keywords: Correlation; Solid solubility; Pharmaceutical compounds; Supercritical carbon dioxide 1. Introduction appearing in recent literature and it was the purpose of this study to develop a useful correlation based on these data of Many applications of supercritical fluid technology have pharmaceutical compounds.
    [Show full text]
  • Research Article Effect of Bioactive Compound of Aronia Melanocarpa on Cardiovascular System in Experimental Hypertension
    Hindawi Oxidative Medicine and Cellular Longevity Volume 2017, Article ID 8156594, 8 pages https://doi.org/10.1155/2017/8156594 Research Article Effect of Bioactive Compound of Aronia melanocarpa on Cardiovascular System in Experimental Hypertension 1 1 1,2 1 Martina Cebova, Jana Klimentova, Pavol Janega, and Olga Pechanova 1Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, Slovakia 2Department of Pathology, Faculty of Medicine, Comenius University, Bratislava, Slovakia Correspondence should be addressed to Martina Cebova; [email protected] Received 4 August 2017; Revised 10 October 2017; Accepted 18 October 2017; Published 30 November 2017 Academic Editor: Victor M. Victor Copyright © 2017 Martina Cebova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Aronia melanocarpa has attracted scientific interest due to its dense contents of different polyphenols. We aimed to analyse effects of Aronia melanocarpa (AME) extract on blood pressure (BP), lipid peroxidation, cytokine level, total NOS activity in the left ventricle (LV), and aorta of L-NAME-induced hypertensive rats. 12-week-old male WKY rats were assigned to the control group and groups treated with AME extract (57.90 mg/kg/day), L-NAME (40 mg/kg/day), or combination of L-NAME (40 mg/kg/day) and AME (57.90 mg/kg/day) in tap water for 3 weeks. NOS activity, eNOS protein expression, and conjugated diene (CD) concentration were determined in the LV and aorta. After 3 weeks of L-NAME treatment, BP was increased by 28% and concomitant treatment with AME reduced it by 21%.
    [Show full text]
  • Novel Modulation of Adenylyl Cyclase Type 2 Jason Michael Conley Purdue University
    Purdue University Purdue e-Pubs Open Access Dissertations Theses and Dissertations Fall 2013 Novel Modulation of Adenylyl Cyclase Type 2 Jason Michael Conley Purdue University Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations Part of the Medicinal-Pharmaceutical Chemistry Commons Recommended Citation Conley, Jason Michael, "Novel Modulation of Adenylyl Cyclase Type 2" (2013). Open Access Dissertations. 211. https://docs.lib.purdue.edu/open_access_dissertations/211 This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact [email protected] for additional information. Graduate School ETD Form 9 (Revised 12/07) PURDUE UNIVERSITY GRADUATE SCHOOL Thesis/Dissertation Acceptance This is to certify that the thesis/dissertation prepared By Jason Michael Conley Entitled NOVEL MODULATION OF ADENYLYL CYCLASE TYPE 2 Doctor of Philosophy For the degree of Is approved by the final examining committee: Val Watts Chair Gregory Hockerman Ryan Drenan Donald Ready To the best of my knowledge and as understood by the student in the Research Integrity and Copyright Disclaimer (Graduate School Form 20), this thesis/dissertation adheres to the provisions of Purdue University’s “Policy on Integrity in Research” and the use of copyrighted material. Approved by Major Professor(s): ____________________________________Val Watts ____________________________________ Approved by: Jean-Christophe Rochet 08/16/2013 Head of the Graduate Program Date i NOVEL MODULATION OF ADENYLYL CYCLASE TYPE 2 A Dissertation Submitted to the Faculty of Purdue University by Jason Michael Conley In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy December 2013 Purdue University West Lafayette, Indiana ii For my parents iii ACKNOWLEDGEMENTS I am very grateful for the mentorship of Dr.
    [Show full text]